The need for novel approaches in assessing the value of COVID-19 vaccines

Numerous Covid-19 vaccine development programs are under way and several vaccines with potentially differing clinical and manufacturing profiles are expected to reach the market. We argue for the need to adopt new approaches for assessing the value of Covid-19 vaccines, calling for clinical, manufacturing and cost aspects to be complemented by societal value considerations to inform the vaccines’ development, reimbursement and pricing decisions.